Biotech convergence is a very innovative area of science that integrates biology, engineering, and data science to improve the health sector and the medical field. It will soon become one of Israel’s main driving forces in the next decade.
The Israel Innovation Authority works closely with universities, government bodies, and private companies just to promote the spirit of competition. The R&D infrastructure is under focus so as to enable faster development of personalized medicine, genetic therapies, and medical technologies.
Israel as the powerhouse of AI, life sciences research, and high-tech emerging technologies has it in its power to assume the leadership position internationally in the field. According to the information collected, there are already 80 companies dealing with a really big portfolio, but they are looking for growth opportunities through partnerships with foreign companies.
Notwithstanding the fact that regulatory barriers continue to be difficult, Israel’s proactivity in this area means it will stay at the forefront of combining bio-convergence technical solutions and medicine. Beyond the promise of economic benefits, this industry will also unleash the unlimited potential of new medical treatments all around the globe.
